Assessing the Role of MicroRNAs in Predicting Breast Cancer Recurrence—A Systematic Review

Mkabaah, Luis Bouz; Davey, Matthew G; Lennon, James C.; Bouz, Ghada; Miller, Nicola; Kerin, Michael J.

doi:10.3390/ijms24087115

Cited by 9 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study proposed that miRNAs might be fundamental elements involve in the cancer cell dormancy and latent metastases, which are related to the recurrence of BC [146]. As a result, knowing differentially expressed circulating miRNAs and tumor-based miRNAs in early-stage BC patients may offer predictive indicators of relapse before the manifestation of recurrence symptoms [147]. These miRNAs can influence abnormal cellular behavior, relapse risk, and, ultimately, survival outcomes.…”

Section: Use Of Mirnas As Prognostic Marker Of Bc Recurrencementioning

confidence: 99%

The Role of MicroRNAs in Breast Cancer and the Challenges of Their Clinical Application

Muñoz,

Pérez-Moreno,

Pérez

et al. 2023

Diagnostics

View full text Add to dashboard Cite

MicroRNAs (miRNAs) constitute a subclass of non-coding RNAs that exert substantial influence on gene-expression regulation. Their tightly controlled expression plays a pivotal role in various cellular processes, while their dysregulation has been implicated in numerous pathological conditions, including cancer. Among cancers affecting women, breast cancer (BC) is the most prevalent malignant tumor. Extensive investigations have demonstrated distinct expression patterns of miRNAs in normal and malignant breast cells. Consequently, these findings have prompted research efforts towards leveraging miRNAs as diagnostic tools and the development of therapeutic strategies. The aim of this review is to describe the role of miRNAs in BC. We discuss the identification of oncogenic, tumor suppressor and metastatic miRNAs among BC cells, and their impact on tumor progression. We describe the potential of miRNAs as diagnostic and prognostic biomarkers for BC, as well as their role as promising therapeutic targets. Finally, we evaluate the current use of artificial intelligence tools for miRNA analysis and the challenges faced by these new biomedical approaches in its clinical application. The insights presented in this review underscore the promising prospects of utilizing miRNAs as innovative diagnostic, prognostic, and therapeutic tools for the management of BC.

show abstract

Section: Use Of Mirnas As Prognostic Marker Of Bc Recurrencementioning

confidence: 99%

The Role of MicroRNAs in Breast Cancer and the Challenges of Their Clinical Application

Muñoz,

Pérez-Moreno,

Pérez

et al. 2023

Diagnostics

View full text Add to dashboard Cite

show abstract

“…Davey et al carried out a systematic review highlighting the ability of miRNAs to be used as biomarkers predictive of the response of early stage HER-2-overexpressing breast cancers to neoadjuvant chemotherapy and/or anti-HER-2 therapies, with 41 miRNAs showing increased expression in patients who responded to neoadjuvant therapy, and 29 miRNAs with reduced expression in patients who responded [ 62 ]. Bouz Mkabaah et al performed a systematic review of the literature, assessing the role of miRNAs in predicting the recurrence of breast cancer, with a total of 44 miRNAs identified as being useful in this goal [ 25 ]. McGuire et al showed that increased expression of miRNA-21 and miRNA-145 in whole blood samples was associated with non-response to neoadjuvant chemotherapy in luminal breast cancer.…”

Section: Mirnas As Biomarkers Of Breast Cancermentioning

confidence: 99%

“…Since the seminal work of these authors, the role of miRNAs in breast cancer has been further elucidated. For example, previous authors have demonstrated the capabilities of miRNAs to predict breast cancer hormone receptor status, others have evaluated the role of miRNAs as therapeutic options in cancer [ 19 , 20 , 21 , 22 ], and several previous reports have correlated miRNA expression profiles with long-term survival outcomes in malignancy [ 23 , 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

Biological Implications of MicroRNAs as Regulators and Biomarkers of Therapeutic Toxicities in Breast Cancer

Syed¹,

Davey²,

Richard³

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Contemporary breast cancer management includes surgical resection combined with a multimodal approach, including chemotherapy, radiotherapy, endocrine therapy, and targeted therapies. Breast cancer treatment is now personalised in accordance with disease and host factors, which has translated to enhanced outcomes for the vast majority of patients. Unfortunately, the treatment of the disease involves patients developing treatment-induced toxicities, with cardiovascular and metabolic side effects having negative implications for long-term quality-of-life metrics. MicroRNAs (miRNAs) are a class of small non-coding ribonucleic acids that are 17 to 25 nucleotides in length, which have utility in modifying genetic expression by working at a post-transcriptional cellular level. MiRNAs have involvement in modulating breast cancer development, which is well described, with these biomarkers acting as important regulators of disease, as well as potential diagnostic and therapeutic biomarkers. This review focuses on highlighting the role of miRNAs as regulators and biomarkers of disease, particularly in breast cancer management, with a specific mention of the potential value of miRNAs in predicting treatment-related cardiovascular toxicity.

show abstract

“…A study by Krug et al highlights a proteogenomic technique that may be used to identify clinical and molecular features of specific tumors for the development of tumor-specific treatment targets [18]. Transcriptomic characterization of malignant breast tumors based on microRNAs is a novel approach currently under ongoing investigation [19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

MicroRNAs as Molecular Biomarkers for the Characterization of Basal-like Breast Tumor Subtype

Tariq,

Richard,

Kerin

2023

Biomedicines

Self Cite

View full text Add to dashboard Cite

Breast cancer is a heterogeneous disease highlighted by the presence of multiple tumor variants and the basal-like breast cancer (BLBC) is considered to be the most aggressive variant with limited therapeutics and a poor prognosis. Though the absence of detectable protein and hormonal receptors as biomarkers hinders early detection, the integration of genomic and transcriptomic profiling led to the identification of additional variants in BLBC. The high-throughput analysis of tissue-specific micro-ribonucleic acids (microRNAs/miRNAs) that are deemed to have a significant role in the development of breast cancer also displayed distinct expression profiles in each subtype of breast cancer and thus emerged to be a robust approach for the precise characterization of the BLBC subtypes. The classification schematic of breast cancer is still a fluid entity that continues to evolve alongside technological advancement, and the transcriptomic profiling of tissue-specific microRNAs is projected to aid in the substratification and diagnosis of the BLBC tumor subtype. In this review, we summarize the current knowledge on breast tumor classification, aim to collect comprehensive evidence based on the microRNA expression profiles, and explore their potential as prospective biomarkers of BLBC.

show abstract

Assessing the Role of MicroRNAs in Predicting Breast Cancer Recurrence—A Systematic Review

Cited by 9 publications

References 42 publications

The Role of MicroRNAs in Breast Cancer and the Challenges of Their Clinical Application

The Role of MicroRNAs in Breast Cancer and the Challenges of Their Clinical Application

Biological Implications of MicroRNAs as Regulators and Biomarkers of Therapeutic Toxicities in Breast Cancer

MicroRNAs as Molecular Biomarkers for the Characterization of Basal-like Breast Tumor Subtype

Contact Info

Product

Resources

About